In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination.

被引：0
|
作者：
Raz, I
Stranks, S
Filipczak, R
Joshi, P
Lertoft, B
Råstam, J
Chow, FC
机构：
[1] Hadassah Hebrew Univ Hosp, Diabet Unit, Jerusalem, Israel
[2] Repatriat Gen Hosp, Daw Pk, Australia
[3] NZOZ Gadent, Diabet Unit, Rawa Mazowiecka, Poland
[4] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[5] Prince Wales Hosp, Diabet & Endocrine Ctr, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：A8 / A8
页数：1
相关论文
共 50 条
  • [41] Risk for Nocturnal Hypoglycemia With Biphasic Insulin Aspart 30 Compared With Biphasic Human Insulin 30 in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis
    Davidson, Jaime A.
    Liebl, Andreas
    Christiansen, Jens S.
    Fulcher, Greg
    Ligthelm, Robert J.
    Brown, Paul
    Gylvin, Titus
    Kawamori, Ryuzo
    CLINICAL THERAPEUTICS, 2009, 31 (08) : 1641 - 1651
  • [42] PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES
    Aagren, M.
    Thomsen, T. L.
    Knudsen, V. K.
    VALUE IN HEALTH, 2009, 12 (03) : A10 - A10
  • [43] Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: Results from the A1chieve study
    El Naggar, Nabil K.
    Soewondo, Pradana
    Khamseh, Mohammad E.
    Chen, Jian-Wen
    Haddad, Jihad
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 98 (03) : 408 - 413
  • [44] Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study
    Shestakova, M.
    Sharma, S. K.
    Almustafa, M.
    Min, K. W.
    Ayad, N.
    Azar, S. T.
    Danciulescu, R.
    Khutsoane, D.
    Guler, S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3209 - 3214
  • [45] Efficacy and safety of twice daily vs. thrice daily injections of biphasic insulin aspart 30 in insulin naive patients with type 2 diabetes inadequately controlled with OADs
    Yang, Wenying
    Ji, Qiuhe
    Zhu, Dalong
    Yang, Jinkui
    Chen, Lulu
    Liu, Zhimin
    Yu, Demin
    Yan, Li
    DIABETES, 2007, 56 : A546 - A546
  • [46] Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes
    Schmoelzer, I
    de Campo, A
    Pressl, H
    Stelzl, H
    Dittrich, P
    Oettl, K
    Wascher, TC
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (03) : 176 - 181
  • [47] Comparison of biphasic insulin aspart and human insulin premix in patients with Type 2 diabetes
    Itoh, Hiroshi
    Morikawa, Akizuki
    Asai, Mahito
    Nishimura, Hideo
    Atoh, Keita
    Mutou, Eiji
    Oshima, Eiji
    Iwashima, Yasunor-I
    Miura, Takanori
    Sekiguchi, Masatomo
    Tani, Mitsunori
    Haneda, Masakazu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S65 - S65
  • [48] Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study
    Khutsoane, D.
    Sharma, S. K.
    Almustafa, M.
    Jang, H. C.
    Azar, S. T.
    Danciulescu, R.
    Shestakova, M.
    Ayad, N. M. A.
    Guler, S.
    Bech, O. M.
    DIABETES OBESITY & METABOLISM, 2008, 10 (03): : 212 - 222
  • [49] Over 75% of patients with type 2 diabetes reached target A1C by adding biphasic insulin aspart 70/30 to optimized metformin and pioglitazone treatment
    Raskin, Philip
    Braceras, Rogelio
    Schwartz, Sherwyn
    Chaykin, Louis
    Chu, Pei-Ling
    Wynne, Alan
    DIABETES, 2006, 55 : A131 - A131
  • [50] IMPROVE (TM) observational study of biphasic insulin aspart 30/70 in patients with Type 2 diabetes mellitus
    Kawamori, Ryuzo
    Valensi, Paul
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2010, 5 (04) : 507 - 516
12345